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Abstract
The role of vitamin D in melanoma is still controversial. Although several Authors described a correlation between vitamin D deficiency and poor survival in metastatic melanoma patients, clinical trials exploring the effects of vitamin D supplementation in this clinical setting were mostly inconclusive. 
However, recent evidence suggests that vitamin D exerts both anti-proliferative effects on tumor cells and immune-modulating activities, that have been widely explored in auto-immune disorders. On the one hand, vitamin D has been shown to inhibit T-helper17 lymphocytes, notoriously involved in the pathogenesis of immune-related adverse events (iAEs) which complicate immune-checkpoint inhibitor (ICI) treatment. On the other hand, vitamin D up-regulates PDL-1 expression on both epithelial and immune cells, suggesting a synergic effect in combination with ICIs, for which further investigation is needed.  














Introduction 
In the past few years, vitamin D anti-cancer properties have been arousing  increasing interest in the field of oncology. In the melanoma setting, most patients suffer from D hypovitaminosis for several reasons, including malnutrition and limited sun exposure, due to the increased risk of both adverse skin events during anti-cancer treatments and metachronous skin malignancies [1]. Moreover, low vitamin D serum levels have been associated with melanoma thickness and poor survival, supporting the hypothesis that vitamin D derivatives might play an important role in cancer prevention and treatment[2]. 
Indeed, the potential effectiveness of adjuvant vitamin D3 (cholecalciferol) administration has been investigated in high-risk melanoma patients, who experienced an improvement in terms of both progression-free survival (PFS) and overall survival (OS) [3]. Nevertheless, this therapeutic approach is still not considered a “standard of care”, since vitamin D has also been shown to exert immune-suppressive effects which could counteract its anti-cancer properties. Indeed, in the tumor microenvironment, vitamin D has been shown  to increase the T-regulatory (Treg)/T-helper 17 (Th-17) cell ratio, resulting in immune-suppression [4].
The role of vitamin D in immune regulation has been extensively investigated in auto-immune disorders such as multiple sclerosis (MS), whose evolution is correlated with  T-cells (mostly Th-17) hyperactivation, and in which high-dose vitamin D3 has been shown to be beneficial [5]. Since Th-17 lymphocytes participate in the onset of the so called immune-related adverse events (irAEs), frequently described in melanoma patients receiving immune checkpoint inhibitors [6], a novel application of vitamin D in this clinical setting could be considered.
Thus, in this review we explored the physiological activities of vitamin D, focusing on its anti-cancer properties and role in immune-system modulation, which could open a new scenario for the management of melanoma patients and irAEs.


Structure and functions of vitamin D 
Vitamin D is a fat-soluble pro-hormone that features 5 different isoforms, including vitamin D2, also known as ergocalciferol, and vitamin D3 (cholecalciferol). 
The latter derives from both exposure to the sun and dietary intake. Indeed, ultraviolet (UV) radiation promotes the conversion of 7-dehydrocholesterol to cholecalciferol and two inactive products, namely lumisterol and tachisterol. The relative amount of vitamin D3 and D2 depend mainly upon the UV wavelength, with the most effective being comprised between 290 and 315 nm. Other factors that modulate vitamin D3 production are skin thickness and pigmentation, as well as the duration of sun exposure [7].
On the other hand, dietary vitamin D  undergoes intestinal absorption through passive diffusion in enterocytes and is subsequently incorporated into chylomicrons, before entering the systemic circulation via mesenteric lymph vessels. Like to other fat-soluble vitamins, vitamin D is mainly stored in adipose tissue [8].
Regardless of its origin, vitamin D is present in a biologically inactive form and must undergo two consecutive hydroxylations for transformation to the corresponding active form, calcitriol. 
Vitamin D effects are mediated by its receptor (VDR), which belongs to the nuclear receptor superfamily. When vitamin D binds the VDR, conformational changes occur in its ligand-binding domain, inducing modifications of co-regulatory molecules, such as defective ribosomal products (DRIP), proto-oncogene tyrosine-protein kinase Src and β-catenin  [9]. Activated VDR binds the so-called vitamin D response elements (VDREs) in target genes, leading to a rearrangement of the chromatin structure  and transcription modulation.
The major endocrine role of vitamin D is  the regulation of calcium homeostasis; this function is exerted by the active metabolite (i.e. 1,25-dihydroxyvitamin D or calcitriol) which targets the kidney, small bowel and bone.  1,25-dihydroxyvitamin D promotes the intestinal absorption of calcium, as well as phosphate and calcium  reabsorption by the kidneys; the latter also contribute to the first step of calcitriol activation through the 24-hydroxylase enzyme [10].
Besides its ability to modulate calcium absorption, 1,25-dihydroxyvitamin D also exerts a direct action on bone homeostasis by binding the VDR expressed  by osteoblasts, which up-regulates  the expression of the receptor activator of the nuclear factor kappa-B ligand (RANKL),  to induce osteoclastogenesis, bone resorption and  calcium release from the bone matrix. 
The existence of extraskeletal effects of 1,25-dihydroxyvitamin D was suggested by the evidence of VDR in tissues and cells that are not involved in the maintenance of calcium homeostasis, such as the pancreas, skin, placenta, brain and activated T cells.  Vitamin D receptors  have also been described on myocytes, although their expression tends to decrease with aging [11]. 
Moreover, the 1-alpha-hydroxylase enzyme (responsible for the production of active 1,25-dihydroxyvitamin D) has been found in macrophages, osteoblasts, keratinocytes, as well as the prostate, colon and breast cells. Synthesis of 1,25-dihydroxyvitamin D outside the bone seems to be involved in the regulation of cell growth, rather than calcium homeostasis. In particular, vitamin D appears to inhibit cell proliferation, while increasing apoptosis and cell differentiation [12].
Among vitamin D target genes, some may be upregulated, such as osteopontin, RANKL, Calbindin-9k, insulin-like growth factor binding protein (IGFBP), and β3 integrin, while others are downregulated, including interleukin genes IL1 and IL12, tumor-necrosis factor alpha (TNF-alpha), epidermal growth factor receptor (EGFR) and telomerase reverse transcriptase (TERT). Vitamin D inhibits mitogen-activated protein kinase (MAPK) signaling through the suppression of the EGFR pathway and IGF receptor (IGFR). Moreover, it induces apoptosis  through the IGFR1/phosphatidylinositol 3-kinase (PI3K)-Akt  pathway, by inhibiting telomerase and downregulating Bcl-2. It also induces BAX and activates caspase cleavage by targeting p27 for degradation, leading to cell-cycle progression. It increases the expression of E-cadherin, which leads to repression of the proto-oncogene MYC [12]. 
Interestingly, a number of immune cells express the VDR, including dendritic cells (DCs), activated T- and B-lymphocytes [13], and it is well known that vitamin D plays a role in macrophage function. Overall, vitamin D is thought to inhibit adaptive immunity, while promoting innate immune responses. A number of studies have suggested that vitamin D regulates the innate immunity against microbial agents. In vitro experiments showed that 1,25-dihydroxyvitamin D can stimulate the production of human cathelicidin, a peptide with antimicrobial properties, by monocyte-macrophages . According to Wang and colleagues [14], 1,25-dihydroxyvitamin D is able to stimulate the production of other antimicrobial peptides, such as  defensin β type 2 and the lipocalin associated with neutrophil gelatinase.

The role of vitamin D in cancer 
Vitamin D has been shown to exert antineoplastic activities, both in vitro and in vivo. The first studies date back to 1981 and described such effects in melanoma cells, whose proliferation was inhibited by 1,25-dihydroxyvitamin D3, and in mouse acute myeloid leukaemia cells, that were successfully differentiated into macrophages [15-17].
The antiproliferative effects of calcitriol partly rely on its direct actions on the cell cycle machinery, as it can increase the expression of the cyclin-dependent kinase (CDK) inhibitors p21 and p27, while decreasing CDK activity. Moreover, it also influences the balance between growth factors and inhibitors and down-regulates the pathways involved in cell growth, such as MAPK and PI3K  [18].
A substantial body of evidence has confirmed that vitamin D can induce the differentiation of cancer cells towards a normal or less malignant phenotype [19]. Many mechanisms have been proposed, including  downregulation of the β-catenin transcriptional activity and the nuclear factor-κB (NF-κB) signaling involved in cell differentiation and proliferation [20]. 
The modulation of NF-κB also suppresses the expression of vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1α (HIF-1α) and IL8. The same occurs also for cycloxygenase-2 (COX-2), the enzyme generating prostaglandin E2, which in turn increases the expression of HIF-1α [21]. Thus, vitamin D can simultaneously suppress inflammation and angiogenesis.
Other studies show that calcitriol regulates the expression of matrix metalloproteinases (MMPs) and adhesion molecules. In particular, while MMP9, integrin α6 and β4 are downregulated, tissue inhibitors of MMP1 and E-cadherin are upregulated by vitamin D, thus reducing the  cancer cell metastatic potential [22].
In order to explore its anti-cancer activity, Lappe et al. designed a randomized placebo-controlled study which showed that daily intake of both vitamin D3 (1100 IU/die) and calcium (1500 mg/die) by post-menopausal women resulted in a significantly decreased risk of cancer (p<0.03) [23-24]. More recently, a strong correlation between exposure to UVB radiation and a reduced risk of cancer has been described [25]. Furthermore, a systematic review concluded that higher serum levels of vitamin D were associated with a lower mortality from breast and colorectal cancer. These data have been also confirmed by a meta-analysis of 12 studies, which showed a protective effect of vitamin D against the development of lung cancer (relative risk = 0.84, P< 0.001) [26].  
Overall, these data suggest that vitamin D may influence cancer onset and prognosis, and a meta-analysis on colorectal cancer identified a 30-40% risk reduction among subjects with high 25-hydroxyvitamin D levels, but for other tumors the association, if any, seems less significant [27. 
The promising data on colorectal cancer prompted a phase III clinical trial in subjects with completely resected colorectal adenomas, who were randomized to receive daily 1000 IU vitamin D3, 1200 mg calcium carbonate, both or neither of them until a follow-up colonoscopy performed 3 to 5 years later, depending upon the clinician's judgment. The study, even if adequately powered, failed to show the effectiveness of any of the regimens in preventing colorectal adenomas [28]. However, the vitamin D3 dosage employed was lower than usual and participants were allowed to take over-the-counter supplements (up to 1000 IU vitamin D and 400 mg calcium), although this behavior was discouraged. 
A meta-analysis on prostate cancer did not show any correlation between its incidence and vitamin D levels [29-30], while the studies on breast cancer yielded conflicting and inconclusive data [31-32]. There is limited evidence in the context of  other malignancies and no definite association has so far been identified [33-34]. The “Vitamin D and Omega-3 Trial” (VITAL: ClinicalTrials.gov Identifier NCT01169259) is an ongoing placebo-controlled study involving over 25,000 healthy subjects, aimed at investigating the ability of vitamin D3 and/or ω-3 fatty acids to prevent cancer, stroke, and heart diseases. Enrollment was completed in March 2014 and the subjects should receive the assigned treatment for an average of 5 years. Since potential risk factors are equally distributed across the experimental arms, the trial is expected to provide robust evidence on the preventative role of vitamin D  [35]. 
On the other hand, most studies investigating the  role of vitamin D levels and cancer prognosis have yielded promising results,  found in prostate and colorectal cancer, and confirmed by a meta-analysis of longitudinal studies [36]. However, the interstudy heterogeneity in terms of vitamin D assessment prevents definitive conclusions from being drawn as to  the role of vitamin D either as a chemopreventive or anti-cancer agent. However, preclinical evidence supports the ongoing studies, which will hopefully lead to conclusive results in the future.

Role of vitamin D in melanoma
Correlation between melanoma risk factors and vitamin D levels          
It has been demonstrated that high vitamin D levels are correlated with a lower risk of melanoma onset and recurrence [37], although it is unclear whether vitamin D is protective in itself or is  a surrogate marker for other protective factors [38]. It has also been hypothesized that an  increased production of vitamin D may reflect a healthier lifestyle which, in turn, confers general protection against cancer [39-40].
Surprisingly, some risk factors for melanoma, such as senescence, high naevi counts and type 1-2 skin phototypes, have been associated with the vitamin D metabolism. In particular, skin type influences vitamin D levels due to the competition between melanin and 7-dehydrocholesterol for UVB photons, that can limit  vitamin D synthesis. Recent evidence suggests that skin pigmentation, throughout the activation of the melanocyte-stimulating hormone (MSH) pathway, is involved in cell survival and proliferation as well as skin inflammation, suggesting a possible relationship between the genes regulating skin pigmentation and those involved in vitamin D metabolism [41]. Several genes  defining human skin pigmentation and sun sensitivity have been identified through candidate and genome-wide association (GWA) studies, explaining the high  variability of vitamin D levels among individuals of different ethnic origin [42]
In this regard, single-nucleotide polymorphisms (SNPs) of the vitamin D binding protein and vitamin D hydroxylase (CYP2R1) genes influence vitamin D levels, while VDR genotypes do not influence vitamin D production in healthy subjects [43]. 
As to senescence, it is well known that the leucocytes telomere length is correlated with naevi counts, melanoma risk and survival.  A recent study [44-45]explored the association between naevi counts, leucocytes telomere length and vitamin D serum levels, demonstrating that high vitamin D levels are associated with higher naevi counts independently of age, weight, height and season of sampling  (p=0.02). 
The naevus count is the strongest risk factor for melanoma, and has been reported to be genetically determined [46]. GWA studies identified a number of SNPs potentially associated with an increased melanoma risk in patients with many naevi [47]. Moreover, a positive correlation between the number of naevi and 25-hydroxyvitamin D levels has been recently reported [48]. Notably, increased naevi counts are correlated with the onset of thinner melanomas, mostly characterized by superficial spread and occurrence in young individuals, whereas low vitamin D levels mostly occur in the elderly and are associated with thicker lesions [49-50]

Clinical data on vitamin D in melanoma
Vitamin D deficiency has been associated with an increased risk of several cancers, including melanoma [51]. This could be explained by the  anti-proliferative effects of vitamin D demonstrated on melanoma cells both in vitro and in vivo [52]. In agreement with these data, high serum vitamin D has been associated with thinner tumors and improved survival, as compared to lower vitamin D levels [53-55].
The correlation between 25-hydroxyvitamin D levels and survival has been reported in large studies, and a pilot randomized placebo-controlled phase II trial (Mel-D ANZMTG 02.09) investigated both the safety and the efficacy of adjuvant vitamin D administration to melanoma patients  [3]. This approach is currently under investigation in the large MelaVid and ViDMe multicenter phase III studies. The former (ClinicalTrials.gov Identifier: NCT01264874) is a double blind trial on vitamin D supplementation for resected stage II melanoma patients who are randomized to receive either 100,000 IU cholecalciferol or placebo every 50 days for up to 3 years, or until relapse. Similarly, in the ViDMe trial (ClinicalTrials.gov Identifier: NCT01748448), monthly treatment with either 100,000 IU vitamin D or placebo is administered for up to 3.5 years, or until relapse. Enrollment of 500  patients in this study, whose primary endpoint is relapse-free survival, is planned. Table 1 summarizes the clinical trials investigating the role of vitamin D in the melanoma setting [56]. 
Currently, melanoma patients are advised to limit sun exposure, while there is no standard recommendation for serum vitamin D measurement or supplementation. Even if sun exposure might improve vitamin D availability, clinicians should stress that vitamin D dietary intake is often necessary to reach adequate serum concentrations [57-60]. Moreover, in melanoma patients with D hypovitaminosis, oral vitamin D supplementation should be preferred over unprotected sun exposure, due to the risk of metachronous skin malignancies [61-63]. Periodical monitoring of serum vitamin D should be performed and high doses (> 5,000 IU/die) avoided to prevent hypercalcemia.
In conclusion, despite the promising preclinical data, further investigation is needed to better establish the role of vitamin D in melanoma pathogenesis and prevention. Besides its direct anti-cancer activity, an increasing body of evidence supports its immune-modulating properties, which could warrant novel clinical applications in this setting, as discussed in the next sections. 
Vitamin D as an immune-modulating agent
Vitamin D exerts a broad range of effects on both innate and adaptive immunity compartments   [64]. As regards the former, macrophages synthesize the VDR, whose expression is induced by stimulation of the toll-like receptor (TLR) 2/1 [65-66]. Vitamin D not only enhances the secretion of anti-microbial peptides like cathelicidin and defensins, which contribute to immunity against intracellular pathogens (e.g. Mycobacterium tuberculosis), but also exerts a direct anti-proliferative activity on tubercle bacilli in vitro [67]. Calcitriol further participates in bacterial clearance by up-regulating the inducible nitric oxide synthase (iNOS) gene [68]. These mechanisms might explain the susceptibility of vitamin D-deficient subjects to tuberculosis.
Recent clinical evidence supports the above-mentioned data, showing a direct correlation between vitamin D administration and serum cathelicidin levels in healthy subjects [69]. A possible molecular mechanism explaining the linkage between these two molecules is the transcriptional induction of the cathelicidin gene by the 25-hydroxyvitamin D-VDR complex, thanks to specific VDREs in the promoter [70]. Interestingly, evolutionary analyses have shown the presence of VDREs in the primate genome only, suggesting that genomic regulation of the immune system by vitamin D may be a relatively recent phylogenesis gain. 
In the field of adaptive immunity, 1,25-dihydroxyvitamin D can inhibit the maturation of DCs and reduce their antigen-presenting capability. Indeed, a reduced expression of human leukocyte antigen (HLA) and costimulatory molecules (e.g. CD80, CD86) has been observed in DCs following exposure to 1,25-dihydroxyvitamin D [71].
Moreover, vitamin D suppresses the secretion of IL12, IL23 and IL6; while IL12 is involved in Th1 cell differentiation, IL2 and IL6 are known to stimulate Th17 development . As a final effect, both Th1 and Th17 levels are reduced by 1,25-dihydroxyvitamin D, causing a predominance of the  Th2 response [72]. Calcitriol also promotes the differentiation of T-reg lymphocytes and the secretion of inhibitory cytokines, such as IL10 [73-74].
In vitro preliminary results have been supported by animal models of auto-immune diseases, such as inflammatory bowel diseases and systemic lupus erythematosus, showing an improvement of pathologic manifestations after vitamin D supplementation [75]  and a significant association between vitamin D intake and a reduced incidence of auto-immune disorders (e.g. type 1 diabetes, Graves thyroiditis and MS) [76-77].  Other studies have demonstrated a relative protection from asthma in VDR gene knock-out mice  while showing an inverse correlation between 1,25-dihydroxyvitamin D levels and the risk of childhood asthma and eczema [78-79]. Moreover, exposure to high levels of 1,25-dihydroxyvitamin D seems to protect from transplanted pancreatic island cells rejection in animal models [80] . 
Interestingly, vitamin D regulates not only lymphocyte differentiation, but also T cell homing. Indeed, it has been shown  to inhibit T cell migration towards lymph nodes and the gut, while promoting the homing process to the skin; such an effect seems to be mediated by specific chemokine receptors like CCR10, whose ligand CCL27 is expressed by keratinocytes [81].  The humoral compartment of immunity is also subject to the regulatory activity of calcitriol, even if this function is less clear. Only activated B lymphocytes express the VDR, whose stimulation inhibits their terminal differentiation into plasma cells and memory B cells [82] .
In conclusion, the overall effect of vitamin D on the immune system consists of stimulating innate immunity  and inhibiting adaptive immunity. The global scenario is even more complicated, since immune cells can synthesize the active form of vitamin D from its circulating precursor. Indeed, DCs express a particular isoform of the 1-alpha-hydroxylase enzyme, which is insensitive to the negative feedback provided by either parathyroid hormone or the final reaction product, while it is stimulated by pro-inflammatory cytokines [83] . It has been suggested that vitamin D activation by macrophages triggers an autocrine loop stimulating their terminal differentiation. This hypothesis is supported by the observation that VDR expression decreases from immature to mature DCs, suggesting some kind of auto-regulatory mechanism in competent antigen-presenting cells [84-85].
 
Potential role of vitamin D in combination with immune-check-point inhibitors
The current management of melanoma patients does not include the routine assessment of vitamin D serum levels nor its administration, due to the conflicting data in literature as well as its well-known immune-suppressive activity. Nevertheless, in the immunotherapy era, we could hypothesize a synergism between this molecule and immune check-point inhibitors (ICIs) for several reasons (Figure 1).
Firstly, vitamin D could enhance the clinical response to immunotherapy by inhibiting tumor cell proliferation, as previously described [??]. Secondly, vitamin D has recently been shown to up-regulate the expression of PDL-1, an immune check-point modulator, on immune cells in inflammatory bowel diseases and human epithelial cells [86-87]. Based on the positive correlation between PDL1 levels and the response to ICIs in melanoma [6], we can speculate about a potential benefit that could derive from the concomitant administration of vitamin D. 
Finally, as previously described in MS [5], vitamin D inhibits Th17 cells. A recent report has indicated that 1,25dihydroxyvitamin D prevents autoimmune disorders in vivo, partially due to its suppressive effect on Th17 cells. In murine models of autoimmune encephalomyelitis,  treatment with 1,25-dihydroxyvitamin D induced an improvement of  paralysis and disease progression, while reducing the Th-17 population in both the peripheral and the central nervous system (CNS)  [88]. 
A recent randomized pilot study has demonstrated that cholecalciferol supplementation is safe and tolerated in patients with MS and exhibits pleiotropic immunomodulatory effects by decreasing IL17 secretion by Th17 cells [5]. Interestingly, the expansion of this population has been correlated with the occurrence of irAEs in melanoma patients receiving ICIs, such as anti-PD1 and anti-CTLA-4 monoclonal antibodies [89-90]. Grade 3-4 drug-related adverse events have been reported in up to 54% of patients receiving nivolumab (anti-PD1) + ipilimumab (anti-CTLA-4), compared to 24% of ipilimumab-treated patients [6]. The most common grade 3-4 adverse events included autoimmune colitis (17%), diarrhea (11%) and elevated alanine aminotransferase levels (11%), requiring systemic immunosuppressive treatment. In particular, glucocorticoids were administered to 82% of patients in the combination group and 50% of those receiving ipilimumab-monotherapy, while the anti-TNF monoclonal antibody infliximab was given to 13% and 9% of these patients, respectively. Despite the complete resolution of most irAEs (80%), trial discontinuation due to drug-related adverse events reached 45% in the combination arm, underlining the need for novel preventative strategies [6]. Moreover, although an effective PD-L1 cutoff has not yet been established, in the subgroup of patients with PD-L1–positive tumors, the objective response rates were numerically higher in the combination than the monotherapy arm [6].
Nowadays, vitamin D monotherapy is not licensed for melanoma management but we speculate that melanoma patients could potentially benefit  from combination therapy with vitamin D and ICIs for both irAE prevention and enhancement of anti-tumor immune response mediated by PDL-1 up-regulation. Further investigation is needed to draw definitive conclusions. 

Conclusions and future perspectives 
A huge debate has arisen as to whether vitamin D should be considered a friend or a foe in the melanoma setting. Indeed, its routine administration to melanoma patients is still not considered a standard of care, despite the promising results in terms of both favorable outcome and safety [3]. This is partially due to its immune-suppressive activity, which could counteract the well-known anti-proliferative effects on cancer cells. 
However, its immune-modulating ability could offer indications  for a novel vitamin D application in melanoma patients receiving immunotherapy. Increasing evidence suggests that irAEs, that are frequent  in this setting, are mediated by Th17 cell hyperactivation and IL17 secretion. Interestingly, in MS patients vitamin D seems to counteract the overactivation of Th17 lymphocytes that contribute to the immune-mediated damage. Thus, further investigation is needed to assess the potential effectiveness of vitamin D administration to melanoma patients undergoing immunotherapy, to reinforce the anti-tumoral response and to prevent and/or limit the onset of irAEs.
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Legend to figure
Figure 1. Representative image of synergic activities between Vitamin D and ICIs 
A) After melanoma diagnosis, most patients reduce sun exposure with consequent D hypovitaminosis which is directly correlated with worse prognosis. B) Stage IV melanoma patients eligible to treatment with immune check-point inhibitors (ICIs) could benefit from vitamin D supplementation due to: 1) down-regulation of T-helper 17 cells responsible for immune-related adverse events (IRAEs); 2) reduction of melanoma cell proliferation and 3) increase of PDL-1 expression on both immune and epithelial cells leading to improvement of clinical response.
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